Back Login to subscribe 🔔 Set Alert

ACET Adicet Bio, Inc. Common Stock

Sector: Healthcare

Industry: Biotechnology

15 min delay

Today's News Sentiment

Loading...

Upcoming Earnings

Loading...

ACET Fundamental Data

Loading...

Similar Companies

Loading...

Loading options…

CALLS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

PUTS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

ACET Insider Transactions

Loading insider data…

ACET News

Date	Headline	Sentiment
	Wedbush Maintains Outperform on Adicet Bio, Raises Price Target to $28	84.21%
	12 Health Care Stocks Moving In Monday's Intraday Session	96.55%
	HC Wainwright & Co. Maintains Buy on Adicet Bio, Raises Price Target to $34	64.44%
	Adicet Bio shares are trading lower after the company announced safety and efficacy data from the Phase 1 study evaluating prulacabtagene leucel as a potential treatment for patients with systemic lupus erythematosus with or without lupus nephritis.	96.55%
	Adicet Bio Announces Safety And Efficacy Data From Phase 1 Study Evaluating Prulacabtagene Leucel In Patients With Systemic Lupus Erythematosus With Or Without Lupus Nephritis; Prula-Cel Generally Well Tolerated With No CRS Greater Than Grade 2 And No IEC-HS Or ICANS	79.1%
	Why Webuy Global Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket	87.68%
	12 Health Care Stocks Moving In Friday's After-Market Session	96.87%
	Adicet Bio shares are trading higher after the company announced it will report clinical data from the Phase 1 study evaluating prulacabtagene leucel as a potential treatment for patients with systemic lupus erythematosus with or without lupus nephritis.	94.49%
	Adicet Bio To Report Clinical Data From Phase 1 Study Evaluating Prulacabtagene Leucel As Potential Treatment For Patients With Systemic Lupus Erythematosus With Or Without Lupus Nephritis On September 28	82.41%
	HC Wainwright & Co. Reiterates Buy on Adicet Bio, Maintains $27 Price Target	88.94%